REDEFINING DIAGNOSTICS

Revolutionizing the efficient use of NGS (Next-Generation Sequencing) in precision diagnostics

Redefining accessible

Genomill Health is a pioneering precision diagnostics company with a mission to disrupt the use of molecular diagnostic tests – liquid biopsies and beyond. We want to harness the use of the Next-Generation-Sequencing in diagnostics to the next level with our proprietary Geno1® pre-sequencing platform, enabling major improvements in performance and scalability.

Our vision is to become the leading technology company within molecular diagnostics and fundamentally transform the global healthcare.

Reduced cost

From 1500 USD to

1499

Increased accuracy

From 0,25% to

< 0.25 %

Faster turn-around-time

From 14 days to

14

Geno1

DRIVEN BY WORLD-CLASS RESEARCH

Our proprietary and patented Geno1® technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and data interpretation.

It truly provides means for vertical progress and enables fundamental improvements in cost, accuracy, turn-around-time and scalability. It unlocks the future.

Join our journey

We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1® for out-licensing and are continuously looking for new long-term partnerships within oncology and other verticals – infectious diseases, NIPT, antibiotic resistance.

Join us in harnessing a true game-changing technology!

Latest news

<font color="#4B9CD2"> Genomeweb: </font> Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

Genomeweb: Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

 NEW YORK – After closing an investment round last month for an undisclosed sum, Finnish firm Genomill Health is aiming…
Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive…